Loading...

Home
ETF
LXRX

LXRX

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

LXRX News

Novo Nordisk Advances Next-Gen Obesity Treatments with LX9851 Trial

Mar 23 2026stocktwits

Lexicon Pharmaceuticals and Novo Nordisk Launch Phase 1 Study for Oral Obesity Drug Candidate LX9851

Mar 23 2026moomoo

Lexicon Pharmaceuticals Q4 2025 Earnings Call Insights

Mar 05 2026seekingalpha

Lexicon Pharmaceuticals Q4 Earnings Beat Expectations

Mar 05 2026seekingalpha

Lexicon Pharmaceuticals to Announce Q4 Earnings on March 5

Mar 04 2026seekingalpha

Chronic Kidney Disease Market Growth Drivers

Mar 03 2026Newsfilter

Lexicon Pharmaceuticals Chairman Buys Over $350K in Shares

Feb 19 2026seekingalpha

Lexicon Pharmaceuticals Closes 32 Million Share Public Offering

Feb 06 2026Newsfilter

Lexicon Pharmaceuticals Prices Public Offering at $1.30 per Share

Jan 30 2026seekingalpha

Lexicon Pharmaceuticals Prices Public Offering at $1.30 per Share

Jan 30 2026Newsfilter

Lexicon Pharmaceuticals Launches Underwritten Public Offering

Jan 29 2026seekingalpha

Lexicon Pharmaceuticals Launches Underwritten Public Offering

Jan 29 2026Newsfilter

Lexicon Pharmaceuticals (LXRX) Advances Pilavapadin to Phase 3 Following Positive FDA Meeting

Jan 21 2026seekingalpha

Lexicon Pharmaceuticals (LXRX) Advances Pilavapadin to Phase 3 After FDA Approval

Jan 21 2026NASDAQ.COM

Progress Software Corp Reports Q4 EPS Beat, Shares Surge 20.5%

Jan 21 2026Benzinga

Lexicon Pharmaceuticals Completes FDA End-of-Phase 2 Meeting, Advancing DPNP Drug Development

Jan 21 2026Globenewswire